Herpes simplex virus vector-mediated gene delivery for the treatment of lower urinary tract pain

Gene Therapy

Volumn 16, Issue 4, 2009, Pages 558-569

  Goins, W F ^a   Goss, J R ^a   Chancellor, M B ^a,b   de Groat, W C ^a   Glorioso, J C ^a   Yoshimura, N ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSAICIN; CHONDROITIN SULFATE; CIMETIDINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIMETHYL SULFOXIDE; DNA; ENKEPHALIN; GLYCOSAMINOGLYCAN; GOLD; HEPARIN; HYDROXYZINE; LIPOSOME; MISOPROSTOL; MONTELUKAST; MORPHINE; NALOXONE; NARCOTIC ANALGESIC AGENT; OPIATE; OPIATE PEPTIDE; OPIATE RECEPTOR; OXYCHLOROSENE; PENTOSAN POLYSULFATE; POTASSIUM CHLORIDE; PREPROENKEPHALIN; PROOPIOMELANOCORTIN; RESINIFERATOXIN; TRAMADOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; URACYST; VIRUS VECTOR;

ANALGESIA; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL TRIAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG METABOLISM; EDEMA; ELECTROPORATION; EROSION; GENE GUN; GENE REPLICATION; GEOGRAPHIC DISTRIBUTION; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOGENICITY; INCIDENCE; INTERSTITIAL CYSTITIS; LIPOSOMAL GENE DELIVERY SYSTEM; MEMBRANE PERMEABILITY; MICTURITION; MUCOSAL EROSION; NEUTROPHIL CHEMOTAXIS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PATHOPHYSIOLOGY; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SIGNAL TRANSDUCTION; TRANSCUTANEOUS NERVE STIMULATION; ULCER; UNSPECIFIED SIDE EFFECT; URINARY TRACT PAIN; VIRAL GENE DELIVERY SYSTEM;

CYSTITIS, INTERSTITIAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; NEURONS, AFFERENT; OPIOID PEPTIDES; SIMPLEXVIRUS; URINARY BLADDER;

SIMPLEXVIRUS;

EID: 64549125138     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.19     Document Type: Article

References (143)

1. Doggweiler-Wiygul R, Blankenship J, MacDiarmid SA. Review on chronic pelvic pain from a urological point of view. World J Urol 2001; 19: 160-165.
2. Batra AK, Hanno PM, de Groat WC. Interstitial cystitis. In: Sant GR (ed.). AUA Update Series, Vol. 19, Lession 2. American Urological Association, 1999.
3. Ratner V. Interstitial cystitis: A chronic inflammatory bladder condition. World J Urol 2001; 19: 157-159.
4. Rivas DA, Chancellor MB, Blaivas JG. Interstitial cystitis. Adv Urol 1994: 229-265.
5. Oravisto KJ. Epidemiology of interstitial cystitis. Ann Chir Gynaecol Fenn 1975; 64: 75-77.
6. Held PJ, Hanno PM, Wein AJ, Pauly MV, Cahn MA Epidemiology of interstitial cystitis. In: Hanno PM, Staskin DR, Krane RJ (eds). Interstitial Cystitis. Springer-Verlag: London, New York, 2002, pp 29-48.
7. Curhan GC, Speizer FE, Hunter DJ, Curhan SG, Stampfer MJ. Epidemiology of interstitial cystitis: A population based study. J Urol 1999; 161: 549-552.
8. Payne CK, Joyce GF, Wise M, Clemens JQ. Interstitial cystitis and painful bladder syndrome. J Urol 2007; 177: 2042-2049.
9. Yoshimura N, Birder LA. Interstitial cystitis and related painful bladder syndromes: Pathophysiology. In: Pasricha PJ, Willis WD, Gebhart GF (eds). Chronic Abdominal and Visceral Pain: Theory and Practice Informa Healthcare: New York, 2007, pp 495-520.
10. Rajasekaran M, Stein P, Parsons CL. Toxic factors in human urine that injure urothelium. Int J Urol 2006; 13: 409-414.
11. Erickson DR. Urine markers of interstitial cystitis. Urology 2001; 57: 15-21.
12. Sant GR, Theoharides TC. Interstitial cystitis. Curr Opin Urol 1999; 9: 297-302.
13. Sant GR, Hanno PM. Interstitial cystitis: Current issues and controversies in diagnosis. Urology 2001; 57: 82-88.
14. Parsons CL. Successful downregulation of bladder sensory nerves with combination of heparin and alkalinized lidocaine in patients with interstitial cystitis. Urology 2005; 65: 45-48.
15. Nickel JC, Egerdie B, Downey J, Singh R, Skehan A, Carr L et al. A real-life multicentre clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulphate for the treatment of interstitial cystitis. BJU Int 2009; 103: 56-60.
16. Nordling J, Jorgensen S, Kallestrup E. Cystistat for the treatment of interstitial cystitis: A 3-year follow-up study. Urology 2001; 57: 123.
17. Morales A, Emerson L, Nickel JC, Lundie M. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. J Urol 1996; 156: 45-48.
18. Nickel JC, Forrest J, Barkin J, Payne C, Mosbaugh P. Safety and efficacy of up to 900 mg/day polysulfate sodium (elmiron) in patients with interstitial cystitis. Urology 2001; 57: 122-123.
19. Nickel JC, Barkin J, Forrest J, Mosbaugh PG, Hernandez-Graulau J, Kaufman D et al. Randomized, double-blind, doseranging study of pentosan polysulfate sodium for interstitial cystitis. Urology 2005; 65: 654-658.
20. Parsons CL, Forrest J, Nickel JC, Evans R, Lloyd LK, Barkin J et al Effect of pentosan polysulfate therapy on intravesical potassium sensitivity. Urology 2002; 59: 329-333.
21. Davis EL, El Khoudary SR, Talbott EO, Davis J, Regan LJ. Safety and efficacy of the use of intravesical and oral pentosan polysulfate sodium for interstitial cystitis: A randomized double-blind clinical trial. J Urol 2008; 179: 177-185.
22. Rossberger J, Fall M, Peeker R. Critical appraisal of dimethyl sulfoxide treatment for interstitial cystitis: Discomfort, side-effects and treatment outcome. Scand J Urol Nephrol 2005; 39: 73-77.
23. Shiga KI, Hirano K, Nishimura J, Niiro N, Naito S, Kanaide H. Dimethyl sulphoxide relaxes rabbit detrusor muscle by decreasing the Ca2+ sensitivity of the contractile apparatus. Br J Pharmacol 2007; 151: 1014-1024.
24. Melchior D, Packer CS, Johnson TC, Kaefer M. Dimethyl sulfoxide: Does it change the functional properties of the bladder wall? J Urol 2003; 170: 253-258.
25. Ghoniem GM, McBride D, Sood OP, Lewis V. Clinical experience with multiagent intravesical therapy in interstitial cystitis patients unresponsive to single-agent therapy. World J Urol 1993; 11: 178-182.
26. Dimitrakov J, Kroenke K, Steers WD, Berde C, Zurakowski D, Freeman MR et al. Pharmacologic management of painful bladder syndrome/ interstitial cystitis: A systematic review. Arch Intern Med 2007; 167: 1922-1929.
27. Sant GR, Propert KJ, Hanno PM, Burks D, Culkin D, Diokno AC et al. A pilot clinical trial of oral pentosan polysulfate and oral hydroxyzine in patients with interstitial cystitis. J Urol 2003; 170: 810-815.
28. Dasgupta P, Sharma SD, Womack C, Blackford HN, Dennis P. Cimetidine in painful bladder syndrome: A histopathological study. BJU Int 2001; 88: 183-186.
29. Bouchelouche K, Horn T, Nordling J, Larsen S, Hald T. Cysteinyl-leukotriene D(4) receptors in smooth muscle cells. Urology 2001; 57: 109.
30. Kelly JD, Young MR, Johnston SR, Keane PF. Clinical response to an oral prostaglandin analogue in patients with interstitial cystitis. Eur Urol 1998; 34: 53-56.
31. van Ophoven A, Hertle L. Long-term results of amitriptyline treatment for interstitial cystitis. J Urol 2005; 174: 1837-1840.
32. van Ophoven A, Pokupic S, Heinecke A, Hertle L. A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis. J Urol 2004; 172: 533-536.
33. Sasaki K, Smith CP, Chuang YC, Lee JY, Kim JC, Chancellor MB. Oral gabapentin (neurontin) treatment of refractory genitourinary tract pain. Tech Urol 2001; 7: 47-49.
34. Agarwal A, Yadav G, Gupta D, Singh PK, Singh U. Evaluation of intra-operative tramadol for prevention of catheter-related bladder discomfort: A prospective, randomized, double-blind study. Br J Anaesth 2008; 101: 506-510.
35. Singh SK, Agarwal MM, Batra YK, Kishore AV, Mandal AK. Effect of lumbar-epidural administration of tramadol on lower urinary tract function. Neurourol Urodyn 2008; 27: 65-70.
36. Erickson DR. Interstitial cystitis: Update on etiologies and therapeutic options. J Womens Health Gend Based Med 1999; 8: 745-758.
37. Foley KM. Opiod analgesics in clinical pain management. In: Akil H, Herz A, Simon EJ (eds). Opioids II. Springer-Verlag, Berlin Heidelberg: New York, 1993, pp 697-744.
38. Way EL. Opoid tolerance and physical dependence and their relationship. In: Akil H, Herz A, Simon EJ (eds). Opioids II. Springer-Verlag: Berlin, Heidelberg, New York, 1993, pp 573-596.
39. Sairanen J, Tammela TL, Leppilahti M, Multanen M, Paananen I, Lehtoranta K et al. Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: A randomized comparative study. J Urol 2005; 174: 2235-2238.
40. Taneja R, Jawade KK. A rational combination of intravesical and systemic agents for the treatment of interstitial cystitis. Scand J Urol Nephrol 2007; 41: 511-515.
41. Habler HJ, Janig W, Koltzenburg M. Activation of unmyelinated afferent fibres by mechanical stimuli and inflammation of the urinary bladder in the cat. J Physiol 1990; 425: 545-562.
42. Janig W, Morrison JF. Functional properties of spinal visceral afferents supplying abdominal and pelvic organs, with special emphasis on visceral nociception. Prog Brain Res 1986; 67: 87-114.
43. de Groat WC. Spinal cord projections and neuropeptides in visceral afferent neurons. Prog Brain Res 1986; 67: 165-187.
44. Yoshimura N, de Groat WC. Neural control of the lower urinary tract. Int J Urol 1997; 4: 111-125.
45. de Groat WC, Nadelhaft I, Milne RJ, Booth AM, Morgan C, Thor K. Organization of the sacral parasympathetic reflex pathways to the urinary bladder and large intestine. J Auton Nerv Syst 1981; 3 135-160.
46. Morgan C, Nadelhaft I, de Groat WC. The distribution of visceral primary afferents from the pelvic nerve to Lissauer's tract and the spinal gray matter and its relationship to the sacral parasympathetic nucleus. J Comp Neurol 1981; 201: 415-440.
47. Thor KB, Hisamitsu T, Roppolo JR, Tuttle P, Nagel J, deGroat WC. Selective inhibitory effects of ethylketocyclazocine on reflex pathways to the external urethral sphincter of the cat. J Pharmacol Exp Ther 1989; 248: 1018-1025.
48. Mallory B, Steers WD, de Groat WC. Electrophysiological study of micturition reflexes in rats. Am J Physiol 1989; 257: R410-R421.
49. Morrison JF. The physiological mechanisms involved in bladder emptying. Scand J Urol Nephrol Suppl 1997; 184: 15-18.
50. Habler HJ, Janig W, Koltzenburg M. Myelinated primary afferents of the sacral spinal cord responding to slow filling and distension of the cat urinary bladder. J Physiol 1993; 463: 449-460.
51. Maggi CA. The dual, sensory and efferent function of the capsaicin-sensitive primary sensory nerves in the bladder and the urethra. In: Maggi CA (ed). Nervous Control of the Urogenital System Harwood Academic Publishers: Chur, Switzerland, Langhorne, PA, USA, 1993, pp 383-422.
52. McMahon SB, Abel C. A model for the study of visceral pain states: chronic inflammation of the chronic decerebrate rat urinary bladder by irritant chemicals. Pain 1987; 28: 109-127.
53. Wen J, Morrison JFB. Sensitization of pelvic afferent neurons from the rat bladder. J Auton Nerv Syst 1996; 58: 187-198.
54. Keast JR, de Groat WC. Segmental distribution and peptide content of primary afferent neurons innervating the urogenital organs and colon of male rats. J Comp Neurol 1992; 319: 615-623.
55. Steers WD, Mackway-Gerardi AM, Ciambotti J, de Groat WC. Alterations in neural pathways to the urinary bladder of the rat in response to streptozotocin-induced diabetes. J Auton Nerv Syst 1994; 47: 83-94.
56. Lundberg JM. Pharmacology of cotransmission in the autonomic nervous system: Integrative aspects on amines, neuropeptides, adenosine triphosphate, amino acids and nitric oxide. Pharmacol Rev 1996; 48: 113-178.
57. Chancellor MB, de Groat WC. Intravesical capsaicin and resiniferatoxin therapy: Spicing up the ways to treat the overactive bladder. J Urol 1999; 162: 3-11.
58. Elbadawi A. Interstitial cystitis: A critique of current concepts with a new proposal for pathologic diagnosis and pathogenesis. Urology 1997; 49: 14-40.
59. Steers WD, Tuttle JB. Neurogenic inflammation and nerve growth factor: possible roles in interstitial cystitis. In: Sant GR (ed). Interstitial Cystitis. Lippincott-Raven: Philadelphia, 1997, pp 67-75.
60. Yoshimura N, Seki S, de Groat WC In: (ed. 451.5, P. N.) Society for Neuroscience. 2002 Abstract Viewer/Itinerary Planner: Washington, DC, 2002.
61. Sengupta JN, Gebhart GF. Mechanosensitive properties of pelvic nerve afferent fibers innervating the urinary bladder of the rat. J Neurophysiol 1994; 72: 2420-2430.
62. Lazzeri M, Beneforti P, Spinelli M, Zanollo A, Barbagli G, Turini D. Intravesical resiniferatoxin for the treatment of hypersensitive disorder: A randomized placebo controlled study. J Urol 2000; 164: 676-679.
63. Payne CK, Mosbaugh PG, Forrest JB, Evans RJ, Whitmore KE, Antoci JP et al. Intravesical resiniferatoxin for the treatment of interstitial cystitis: A randomized, double-blind, placebo controlled trial. J Urol 2005; 173: 1590-1594.
64. Johansson SL, Ogawa K, Fall M. The pathology of interstitial cystitis. In: Sant GR (ed). Interstitial Cystitis. Lippincott-Raven: Philadelphia, 1997, pp 143-151.
65. Theoharides TC, Kempuraj D, Sant GR. Mast cell involvement in interstitial cystitis: A review of human and experimental evidence. Urology 2001; 57: 47-55.
66. Dmitrieva N, McMahon SB. Sensitisation of visceral afferents by nerve growth factor in the adult rat. Pain 1996; 66: 87-97.
67. England S, Bevan S, Docherty RJ. PGE2 modulates the tetrodotoxin-resistant sodium current in neonatal rat dorsal root ganglion neurones via the cyclic AMP-protein kinase A cascade. J Physiol 1996; 495 (Part 2): 429-440.
68. Gold MS, Reichling DB, Shuster MJ, Levine JD. Hyperalgesic agents increase a tetrodotoxin-resistant Na+ current in nociceptors. Proc Natl Acad Sci USA 1996; 93: 1108-1112.
69. Nicol GD, Vasko MR, Evans AR. Prostaglandins suppress an outward potassium current in embryonic rat sensory neurons. J Neurophysiol 1997; 77: 167-176.
70. Yoshimura N, Bennett NE, Hayashi Y, Ogawa T, Nishizawa O, Chancellor MB et al. Bladder overactivity and hyperexcitability of bladder afferent neurons after intrathecal delivery of nerve growth factor in rats. J Neurosci 2006; 26: 10847-10855.
71. Lanteri-Minet M, Bon K, de Pommery J, Michiels JF, Menetrey D. Cyclophosphamide cystitis as a model of visceral pain in rats: Model elaboration and spinal structures involved as revealed by the expression of c-Fos and Krox-24 proteins. Exp Brain Res 1995; 105: 220-232.
72. Kirimoto T, Nakano K, Irimura K, Hayashi Y, Matsuura N, Kiniwa M et al. Beneficial effects of suplatast tosilate (IPD-1151T) in a rat cystitis model induced by intravesical hydrochloric acid. BJU Int 2007; 100: 935-939.
73. Yoshimura N, de Groat WC. Increased excitability of afferent neurons innervating rat urinary bladder after chronic bladder inflammation. J Neurosci 1999; 19: 4644-4653.
74. Sculptoreanu A, de Groat WC, Buffington CA, Birder LA. Abnormal excitability in capsaicin-responsive DRG neurons from cats with feline interstitial cystitis. Exp Neurol 2005; 193: 437-443.
75. Kakidani H, Furutani Y, Takahashi H, Noda M, Morimoto Y, Hirose T et al. Cloning and sequence analysis of cDNA for porcine beta-neo-endorphin/dynorphin precursor. Nature 1982; 298: 245-249.
76. Nakanishi S, Inoue A, Kita T, Nakamura M, Chang AC, Cohen SN et al Nucleotide sequence of cloned cDNA for bovine corticotropin-beta-lipotropin precursor. Nature 1979; 278: 423-427.
77. Noda M, Furutani Y, Takahashi H, Toyosato M, Hirose T, Inayama S et al. Cloning and sequence analysis of cDNA for bovine adrenal preproenkephalin. Nature 1982; 295: 202-206.
78. Wang JB, Imai Y, Eppler CM, Gregor P, Spivak CE, Uhl GR. Mu opiate receptor: CDNA cloning and expression. Proc Natl Acad Sci USA 1993; 90: 10230-10234.
79. Chen Y, Mestek A, Liu J, Hurley JA, Yu L. Molecular cloning and functional expression of a mu-opioid receptor from rat brain. Mol Pharmacol 1993; 44: 8-12.
80. Fukuda K, Kato S, Mori K, Nishi M, Takeshima H. Primary structures and expression from cDNAs of rat opioid receptor delta- and mu-subtypes. FEBS Lett 1993; 327: 311-314.
81. Thompson RC, Mansour A, Akil H, Watson SJ. Cloning and pharmacological characterization of a rat mu opioid receptor. Neuron 1993; 11 903-913.
82. Minami M, Onogi T, Toya T, Katao Y, Hosoi Y, Maekawa K et al. Molecular cloning and in situ hybridization histochemistry for rat mu-opioid receptor. Neurosci Res 1994; 18: 315-322.
83. Yasuda K, Raynor K, Kong H, Breder CD, Takeda J, Reisine T et al. Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. Proc Natl Acad Sci USA 1993; 90: 6736-6740.
84. Mansour A, Thompson RC, Akil H, Watson SJ. Delta opioid receptor mRNA distribution in the brain: Comparison to delta receptor binding and proenkephalin mRNA. J Chem Neuroanat 1993; 6: 351-362.
85. Kieffer BL, Befort K, Gaveriaux-Ruff C, Hirth CG. The delta-opioid receptor: Isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci USA 1992; 89: 12048-12052.
86. Evans CJ, Keith Jr DE, Morrison H, Magendzo K, Edwards RH. Cloning of a delta opioid receptor by functional expression. Science 1992; 258: 1952-1955.
87. Nishi M, Takeshima H, Fukuda K, Kato S, Mori K. cDNA cloning and pharmacological characterization of an opioid receptor with high affinities for kappa-subtype-selective ligands. FEBS Lett 1993; 330: 77-80.
88. Minami M, Toya T, Katao Y, Maekawa K, Nakamura S, Onogi T et al. Cloning and expression of a cDNA for the rat kappa-opioid receptor. FEBS Lett 1993; 329: 291-295.
89. Meng F, Xie GX, Thompson RC, Mansour A, Goldstein A, Watson SJ et al Cloning and pharmacological characterization of a rat kappa opioid receptor. Proc Natl Acad Sci USA 1993; 90: 9954-9958.
90. Li S, Zhu J, Chen C, Chen YW, Deriel JK, Ashby B et al. Molecular cloning and expression of a rat kappa opioid receptor. Biochem J 1993; 295 (Part 3): 629-633.
91. Chen Y, Mestek A, Liu J, Yu L. Molecular cloning of a rat kappa opioid receptor reveals sequence similarities to the mu and delta opioid receptors. Biochem J 1993; 295 (Part 3): 625-628.
92. Yaksh TL. The spinal actions of opiods. In: Akil H, Herz A, Simon EJ (eds). Opioids II. Springer-Verlag: Berlin, Heidelberg, New York, 1993, pp 53-90.
93. Hiller JM, Simon EJ, Crain SM, Peterson ER. Opiate receptors in cultures of fetalmouse dorsal root ganglia (DRG) and spinal cord: Predominance in DRG neurites. Brain Res 1978; 145: 396-400.
94. Fields HL, Emson PC, Leigh BK, Gilbert RF, Iversen LL. Multiple opiate receptor sites on primary afferent fibres. Nature 1980; 284: 351-353.
95. Stein C. The control of pain in peripheral tissue by opioids. N Engl J Med 1995; 332: 1685-1690.
96. Stein C, Yassouridis A. Peripheral morphine analgesia. Pain 1997; 71: 119-121.
97. Barber A, Gottschlich R. Opioid agonists and antagonists: An evaluation of their peripheral actions in inflammation. Med Res Rev 1992; 12: 525-562.
98. Stein C. Peripheral mechanisms of opioid analgesia. Anesth Analg 1993; 76: 182-191.
99. Su X, Sengupta JN, Gebhart GF. Effects of opioids on mechanosensitive pelvic nerve afferent fibers innervating the urinary bladder of the rat. J Neurophysiol 1997; 77: 1566-1580.
100. Su X, Sengupta JN, Gebhart GF. Effects of kappa opioid receptor-selective agonists on responses of pelvic nerve afferents to noxious colorectal distension. J Neurophysiol 1997; 78: 1003-1012.
101. Attali B, Saya D, Nah SY, Vogel Z. Kappa opiate agonists inhibit Ca2+ influx in rat spinal cord-dorsal root ganglion cocultures. Involvement of a GTP-binding protein. J Biol Chem 1989; 264: 347-353.
102. Dunlap K, Fischbach GD. Neurotransmitters decrease the calcium conductance activated by depolarization of embryonic chick sensory neurones. J Physiol 1981; 317: 519-535.
103. Werz MA, Macdonald RL. Heterogeneous sensitivity of cultured dorsal root ganglion neurones to opioid peptides selective for mu- and delta-opiate receptors. Nature 1982; 299: 730-733.
104. Jessell TM, Dodd J. Neurotransmitters and differentiation antigens in subsets of sensory neurons projecting to the spinal dorsal horn. Res Publ Assoc Res Nerv Ment Dis 1986; 64: 111-133.
105. Yaksh TL, Jessell TM, Gamse R, Mudge AW, Leeman SE. Intrathecal morphine inhibits substance P release from mammalian spinal cord in vivo. Nature 1980; 286: 155-157.
106. Zieglgansberger W, Sutor B. Responses of substantia gelatinosa neurons to putative neurotransmitters in an in vitro preparation of the adult rat spinal cord. Brain Res 1983; 279: 316-320.
107. de Groat WC, Yoshimura N. Pharmacology of the lower urinary tract. Annu Rev Pharmacol Toxicol 2001; 41: 691-721.
108. de Groat WC, Booth AM, Yoshimura N In: Maggi CA (ed) Nervous Control of the Urogenital System. Harwood Academic Publishers: Chur, Switzerland; Langhorne, PA, USA, 1993, pp 227-290.
109. Booth AM, Hisamitsu T, Kawatani M, de Groat WC. Regulation of urinary bladder capacity by endogenous opioid peptides. J Urol 1985; 133: 339-342.
110. Downie JW. Pharmacological manipulation of central micturition circuitry. Curr Opin Central Periph Nerv Sys 1999; 1: 231-239.
111. Dray A, Metsch R. Inhibition of urinary bladder contractions by a spinal action of morphine and other opioids. J Pharmacol Exp Ther 1984; 231: 254-260.
112. Thor KB, Morgan C, Nadelhaft I, Houston M, de Groat WC. Organization of afferent and efferent pathways in the pudendal nerve of the female cat. J Comp Neurol 1989; 288: 263-279.
113. Hisamitsu T, de Groat WC. The inhibitory effect of opioid peptides and morphine applied intrathecally and intracerebro-ventricularly on the micturition reflex in the cat. Brain Res 1984; 298: 51-65.
114. Mallory BS, Roppolo JR, de Groat WC. Pharmacological modulation of the pontine micturition center. Brain Res 1991; 546: 310-320.
115. Chuang YC, Fraser MO, Yu Y, Beckel JM, Seki S, Nakanishi Y et al. Analysis of the afferent limb of the vesicovascular reflex using neurotoxins, resiniferatoxin and capsaicin. Am J Physiol Regul Integr Comp Physiol 2001; 281: R1302-R1310.
116. Craft RM, Henley SR, Haaseth RC, Hruby VJ, Porreca F. Opioid antinociception in a rat model of visceral pain: Systemic versus local drug administration. J Pharmacol Exp Ther 1995; 275: 1535-1542.
117. Meen M, Coudore-Civiale MA, Eschalier A, Boucher M. Involvement of hypogastric and pelvic nerves for conveying cystitis induced nociception in conscious rats. J Urol 2001; 166: 318-322.
118. Chancellor MB, Yoshimura N, Pruchnic R, Huard J. Gene therapy strategies for urological dysfunction. Trends Mol Med 2001; 7: 301-306.
119. Burton EA, Wechuck JB, Wendell SK, Goins WF, Fink DJ, Glorioso JC. Multiple applications for replication-defective herpes simplex virus vectors. Stem Cells 2001; 19: 358-377.
120. Goss JR, Goins WF, Glorioso JC. Gene therapy applications for the treatment of neuropathic pain. Expert Rev Neurother 2007; 7: 487-506.
121. Fraser MO, Lavelle JP, Sacks MS, Chancellor MB. The future of bladder control-intravesical drug delivery, a pinch of pepper, and gene therapy. Rev Urol 2002; 4: 1-11.
122. Nogawa M, Yuasa T, Kimura S, Tanaka M, Kuroda J, Sato K et al. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest 2005; 115: 978-985.
123. Tyagi P, Wu PC, Chancellor M, Yoshimura N, Huang L. Recent advances in intravesical drug/gene delivery. Mol Pharm 2006; 3: 369-379.
124. Iwashita H, Yoshida M, Nishi T, Otani M, Ueda S. In vivo transfer of a neuronal nitric oxide synthase expression vector into the rat bladder by electroporation. BJU Int 2004; 93: 1098-1103.
125. Otani M, Yoshida M, Iwashita H, Kawano Y, Miyamae K, Inadome A et al Electroporation-mediated muscarinic M3 receptor gene transfer into rat urinary bladder. Int J Urol 2004; 11: 1001-1008.
126. Yoo JJ, Soker S, Lin LF, Mehegan K, Guthrie PD, Atala A. Direct in vivo gene transfer to urological organs. J Urol 1999; 162 1115-1118.
127. Chuang YC, Chou AK, Wu PC, Chiang PH, Yu TJ, Yang LC et al. Gene therapy for bladder pain with gene gun particle encoding pro-opiomelanocortin cDNA. J Urol 2003; 170: 2044-2048.
128. Chuang YC, Chuang YC, Yang LC, Chiang PH, Kang HY, Ma WL et al. Gene gun particle encoding preproenkephalin cDNA produces analgesia against capsaicin-induced bladder pain in rats. Urology 2005; 65: 804-810.
129. Werthman PE, Drazan KE, Rosenthal JT, Khalili R, Shaked A. Adenoviral-p53 gene transfer to orthotopic and peritoneal murine bladder cancer. J Urol 1996; 155: 753-756.
130. Engler H, Anderson SC, Machemer TR, Philopena JM, Connor RJ, Wen SF et al. Ethanol improves adenovirus-mediated gene transfer and expression to the bladder epithelium of rodents. Urology 1999; 53: 1049-1053.
131. Connor RJ, Connor RJ, Engler H, Machemer T, Philopena JM, Horn MT et al. Identification of polyamides that enhance adenovirus-mediated gene expression in the urothelium. Gene Therapy 2001; 8: 41-48.
132. Lin LF, Zhu G, Yoo JJ, Soker S, Sukhatme VP, Atala A. A system for the enhancement of adenovirus mediated gene transfer to uro-epithelium. J Urol 2002; 168: 813-818.
133. Ramesh N, Memarzadeh B, Ge Y, Frey D, VanRoey M, Rojas V et al. Identification of pretreatment agents to enhance adenovirus infection of bladder epithelium. Mol Ther 2004; 10: 697-705.
134. Lee SS, Eisenlohr LC, McCue PA, Mastrangelo MJ, Lattime EC. Intravesical gene therapy: in vivo gene transfer using recombinant vaccinia virus vectors. Cancer Res 1994; 54: 3325-3328.
135. Siemens DR, Austin JC, See WA, Tartaglia J, Ratliff TL. Evaluation of gene transfer efficiency by viral vectors to murine bladder epithelium. J Urol 2001; 165: 667-671.
136. Brooks AD, Ng B, Liu D, Brownlee M, Burt M, Federoff HJ et al. Specific organ gene transfer in vivo by regional organ perfusion with herpes viral amplicon vectors: Implications for local gene therapy. Surgery 2001; 129: 324-334.
137. Yokoyama H, Sasaki K, Franks ME, Goins WF, Goss JR, Degroat WC et al Gene therapy for bladder overactivity and nociception with herpes simplex virus vectors expressing preproenkephalin. Hum Gene Ther 2008; 20: 63-71.
138. Sasaki K, Chancellor MB, Goins WF, Phelan MW, Glorioso JC, de Groat WC et al. Gene therapy using replication-defective herpes simplex virus vectors expressing nerve growth factor in a rat model of diabetic cystopathy. Diabetes 2004; 53: 2723-2730.
139. Goins WF, Yoshimura N, Phelan MW, Yokoyama T, Fraser MO, Ozawa H et al. Herpes simplex virus mediated nerve growth factor expression in bladder and afferent neurons: Potential treatment for diabetic bladder dysfunction. J Urol 2001; 165: 1748-1754.
140. Goss JR, Mata M, Goins WF, Wu HH, Glorioso JC, Fink DJ. Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. Gene Therapy 2001; 8 551-556.
141. Goss JR, Harley CF, Mata M, O'Malley ME, Goins WF, Hu X et al. Herpes vector-mediated expression of proenkephalin reduces bone cancer pain. Ann Neurol 2002; 52: 662-665.
142. Hao S, Mata M, Goins W, Glorioso JC, Fink DJ. Transgene-mediated enkephalin release enhances the effect of morphine and evades tolerance to produce a sustained antiallodynic effect in neuropathic pain. Pain 2003; 102: 135-142.
143. Saitoh C, Chancellor MB, de Groat WC, Yoshimura N. Effects of intravesical instillation of resiniferatoxin on bladder function and nociceptive behavior in freely moving, conscious rats. J Urol 2008; 179: 359-364.